Department of Pharmaceutical Sciences and Technology, Maharaja Ranjit Singh Punjab Technical University, Bathinda, Punjab, 151001, India.
Government College of Pharmacy, Rohru, Shimla, Himachal Pradesh, 171207, India.
Inflammopharmacology. 2019 Aug;27(4):663-677. doi: 10.1007/s10787-019-00580-x. Epub 2019 Mar 14.
Alzheimer's disease (AD) is a neurodegenerative disease that is of high importance to the neuroscience world, yet the complex pathogenicity is not fully understood. Inflammation is usually observed in AD and could implicate both beneficial or detrimental effects depending on the severity of the disease. During initial AD pathology, microglia and astrocyte activation is beneficial since they are involved in amyloid-beta clearance. However, with the progression of the disease, activated microglia elicit detrimental effects by the overexpression of pro-inflammatory cytokines such as interleukin (IL)-1β, IL-6, and tumor necrosis factor-α (TNF-α) bringing forth neurodegeneration in the surrounding brain regions. This results in decline in Aβ clearance by microglia; Aβ accumulation thus increases in the brain resulting in neuroinflammation. Thus, Aβ accumulation is the effect of increased release of pro-inflammatory molecules. Reactive astrocytes acquire gain of toxic function and exhibits neurotoxic effects with loss of neurotrophic functions. Astrocyte dysfunctioning results in increased release of cytokines and inflammatory mediators, neurodegeneration, decreased glutamate uptake, loss of neuronal synapses, and ultimately cognitive deficits in AD. We discuss the role of intracellular signaling pathways in the inflammatory responses produced by astrocytes and microglial activation, including the glycogen synthase kinase-3β, nuclear factor kappa B cascade, mitogen-activated protein kinase pathways and c-Jun N-terminal kinase. In this review, we describe the role of neuroinflammation in the chronicity of AD pathogenesis and an overview of the recent research towards the development of new therapies to treat this disorder.
阿尔茨海默病(AD)是一种神经退行性疾病,对神经科学领域非常重要,但复杂的发病机制尚未完全了解。AD 通常会观察到炎症,其影响可能有益也可能有害,具体取决于疾病的严重程度。在 AD 早期病理中,小胶质细胞和星形胶质细胞的激活是有益的,因为它们参与了淀粉样蛋白-β的清除。然而,随着疾病的进展,激活的小胶质细胞通过过度表达促炎细胞因子(如白细胞介素-1β、白细胞介素-6 和肿瘤坏死因子-α)产生有害影响,从而导致周围脑区的神经退行性变。这导致小胶质细胞清除 Aβ 的能力下降;Aβ 在大脑中的积累增加,导致神经炎症。因此,Aβ 的积累是促炎分子释放增加的结果。反应性星形胶质细胞获得毒性功能,并表现出神经毒性作用,同时失去神经营养功能。星形胶质细胞功能障碍导致细胞因子和炎症介质的释放增加、神经退行性变、谷氨酸摄取减少、神经元突触丧失,最终导致 AD 认知功能障碍。我们讨论了细胞内信号通路在星形胶质细胞和小胶质细胞激活产生的炎症反应中的作用,包括糖原合酶激酶-3β、核因子 kappa B 级联、丝裂原激活蛋白激酶途径和 c-Jun N-末端激酶。在这篇综述中,我们描述了神经炎症在 AD 发病机制慢性化中的作用,并概述了最近针对开发治疗这种疾病的新疗法的研究。